<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">persmed</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал персонализированной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal for Personalized Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2782-3806</issn><issn pub-type="epub">2782-3814</issn><publisher><publisher-name>ФОНД АЛМАЗОВА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2782-38062023-3-2-98-106</article-id><article-id custom-type="elpub" pub-id-type="custom">persmed-153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL CASES</subject></subj-group></article-categories><title-group><article-title>Гипертрофическая кардиомиопатия у спортсмена, протекавшая под маской спортивного ремоделирования. Вторичная профилактика внезапной сердечной смерти. Разбор клинического случая</article-title><trans-title-group xml:lang="en"><trans-title>Hypertrophic cardiomyopathy in an athlete, occurring under the mask of sports remodeling. Secondary prevention of sudden cardiac death. Analysis of a clinical case</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Леонтьева</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Leontyeva</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Леонтьева Ирина Викторовна - доктор медицинских наук, профессор, главный научный сотрудник отдела детской кардиологии и аритмологии Научно-исследовательского клинического института педиатрии имени академика Ю. Е. Вельтищева.</p><p>Ул. Талдомская, 2, Москва, 125412</p></bio><bio xml:lang="en"><p>Leontyeva Irina V. - MD, Professor, Chief Researcher of the Department of Pediatric Cardiology and Arrhythmology of the Research Clinical Institute of Pediatrics named after Academician Yu. E. Veltischev of the N. I. Pirogov RNIMU.</p><p>Taldomskaya str., 2, Moscow, 125412</p></bio><email xlink:type="simple">lirina2006@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пресова</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Presova</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пресова Виктория Вадимовна - ординатор отдела детской кардиологии и аритмологии Научно-исследовательского клинического института педиатрии имени академика Ю. Е. Вельтищева.</p><p>Москва</p></bio><bio xml:lang="en"><p>Presova Victoria V., resident of the Department of Pediatric Cardiology and Arrhythmology of the Research Clinical Institute of Pediatrics named after Academician Yu. E. Veltischev of the N. I. Progov RNIMU.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное автономное бюджетное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации, Обособленное структурное подразделение «Научно-исследовательский клинический институт педиатрии имени академика Ю.Е. Вельтищева»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian National Research Medical University named after N.I. Pirogov, Scientific Research Clinical Institute of Pediatrics named after Academician Yu.E. Veltishchev</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>05</month><year>2023</year></pub-date><volume>3</volume><issue>2</issue><fpage>98</fpage><lpage>106</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Леонтьева И.В., Пресова В.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Леонтьева И.В., Пресова В.В.</copyright-holder><copyright-holder xml:lang="en">Leontyeva I.V., Presova V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://persmed.elpub.ru/jour/article/view/153">https://persmed.elpub.ru/jour/article/view/153</self-uri><abstract><p>Гипертрофическая кардиомиопатия (ГКМП) — тяжелое заболевание сердца, характеризующееся высокими показателями внезапной смертности, особенно у лиц молодого возраста. Оптимизация тактики лечения детей с ГКМП с целью улучшения прогноза остается одной из актуальных задач кардиологии. Представлено клиническое наблюдение юноши 15 лет с умеренной гипертрофией миокарда и асимптоматичным течением ГКМП, в связи с чем заболевание длительно не диагностировалось. Мальчик занимался профессиональным спортом, в ходе соревнования он внезапно потерял сознание, возникла клиническая смерть. Только своевременные реанимационные мероприятия позволили сохранить жизнь пациенту. Была проведена имплантация кардиовертера-дефибриллятора в качестве вторичной профилактики ВСС (1 класс показаний). Подчеркивается важность своевременного обследования асимптоматичных спортсменов с гипертрофией миокарда для дифференциальной диагностики между ГКМП и ремоделированием миокарда на фоне интенсивных физических нагрузок («сердце атлета»). Показана важность решения вопроса о недопустимости интенсивных физических нагрузок даже при асимптоматичном течении ГКМП. Установлено, что интенсивные спортивные нагрузки выступают триггером остановки сердца у пациентов с ГКМП. Ретроспективный расчет риска ВСС на основании HCM risc-SDD calculator (калькулятора риска ВСС при ГКМП) показал 3,19 %, что соответствовало низкому риску. Подчеркивается возможность ВСС у пациентов с ГКМП даже при расчетном низком риске, что требует дальнейших исследований по поиску предикторов неблагоприятного исхода.</p></abstract><trans-abstract xml:lang="en"><p>HCMP is a severe heart disease characterized by high rates of sudden mortality, especially in young people. Optimization of the tactics of treatment of children with HCMP in order to improve the prognosis remains one of the urgent tasks of cardiology. A clinical case of a 15-yearold boy with moderate myocardial hypertrophy and an asymptomatic course of HCMP is presented, in connection with which the disease was not diagnosed for a long time. The boy was engaged in professional sports, during the competition he suddenly lost consciousness, clinical death occurred. Only timely resuscitation measures allowed to save the patient’s life. Implantation of a cardioverter defibrillator was performed as a secondary prevention of SCD (class 1 indications). The importance of timely examination of asymptomatic athletes with myocardial hypertrophy for differential diagnosis between HCMP and myocardial remodeling against the background of intense physical exertion (“athlete’s heart”) is emphasized. The importance of solving the issue of the inadmissibility of intense physical exertion, even with an asymptomatic course of HCMP, is shown. It should be remembered that it has been established that intense sports loads act as a trigger for cardiac arrest in patients with HCMP. Retrospective calculation of SCD risk based on HCM risc-SDD calculator/The BCC risk calculator at GCMP showed 3.19 %, which corresponded to a low risk. The possibility of SCD in patients with HCMP is emphasized, even with an estimated low risk, which requires further research to find predictors of an unfavorable outcome.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>внезапная сердечная смерть</kwd><kwd>вторичная профилактика внезапной сердечной смерти</kwd><kwd>гипертрофическая кардиомиопатия</kwd><kwd>имплантируемый кардиовертердефибриллятор</kwd><kwd>спортивное ремоделирование</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertrophic cardiomyopathy</kwd><kwd>implantation of a cardioverter defibrillator</kwd><kwd>secondary prevention of sudden cardiac death</kwd><kwd>sports remodeling</kwd><kwd>sudden cardiac death</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J 2014 /eurheartj/ehu284. www.escardio.org</mixed-citation><mixed-citation xml:lang="en">Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J 2014 /eurheartj/ehu284. www.escardio.org</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Maron B, Spirito P, Ackerman M, et al. Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic Cardiomyopathy. J Amer Coll Cardiol. 2013; 61( 14): 1527–1535.</mixed-citation><mixed-citation xml:lang="en">Maron B, Spirito P, Ackerman M, et al. Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillators in Children and Adolescents With Hypertrophic Cardiomyopathy. J Amer Coll Cardiol. 2013; 61( 14): 1527–1535.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Colan S D, Lipshultz SE, Lowe AM, et al. Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children. Findings From the Pediatric Cardiomyopathy Registry Circulation. 2007;115(6):773–781.</mixed-citation><mixed-citation xml:lang="en">Colan S D, Lipshultz SE, Lowe AM, et al. Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children. Findings From the Pediatric Cardiomyopathy Registry Circulation. 2007;115(6):773–781.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lipshultz SE, Orav EJ, Wilkinson JD, et al. Risk stratification at the time of diagnosis for children with hypertrophic cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry Study Group. Lancet 2013; 382(9908): 1889–1897.</mixed-citation><mixed-citation xml:lang="en">Lipshultz SE, Orav EJ, Wilkinson JD, et al. Risk stratification at the time of diagnosis for children with hypertrophic cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry Study Group. Lancet 2013; 382(9908): 1889–1897.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Shaddy RE, Penny DJ, Feltes TF, et al. (2021). Moss &amp; Adams’ Heart Disease in infants, Children, and Adolescents. Including the Fetus and Young Adult (Shaddy) 10 ed.</mixed-citation><mixed-citation xml:lang="en">Shaddy RE, Penny DJ, Feltes TF, et al. (2021). Moss &amp; Adams’ Heart Disease in infants, Children, and Adolescents. Including the Fetus and Young Adult (Shaddy) 10 ed.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bharucha T, Lee KJ, Daubeney Pl, et al. Sudden death in childhood cardiomyopathy: Results from a longterm national population-based study. J Am Coll Cardiol. 2015; 65(21): 2302–2310.</mixed-citation><mixed-citation xml:lang="en">Bharucha T, Lee KJ, Daubeney Pl, et al. Sudden death in childhood cardiomyopathy: Results from a longterm national population-based study. J Am Coll Cardiol. 2015; 65(21): 2302–2310.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Maron B, Rowin E, Casey S, et al. Hypertrophic Cardiomyopathy in Children, Adolescents,and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies Circulation. 2016;133(1):62–73.</mixed-citation><mixed-citation xml:lang="en">Maron B, Rowin E, Casey S, et al. Hypertrophic Cardiomyopathy in Children, Adolescents,and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies Circulation. 2016;133(1):62–73.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018 Oct 2;138(14):1387–1398. DOI: 10.1161/CIRCULATIONAHA.117.033200. Epub 2018 Aug 23. PMID: 30297972; PMCID: PMC6170149.</mixed-citation><mixed-citation xml:lang="en">Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018 Oct 2;138(14):1387–1398. DOI: 10.1161/CIRCULATIONAHA.117.033200. Epub 2018 Aug 23. PMID: 30297972; PMCID: PMC6170149.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation. 2009; 119(8):1085–1092.</mixed-citation><mixed-citation xml:lang="en">Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation. 2009; 119(8):1085–1092.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">D’Ascenzi F, Valentini F, Pistoresi S, et al. Causes of sudden cardiac death in young athletes and nonathletes: systematic review and meta-analysis: Sudden cardiac death in the young. Trends Cardiovasc Med. 2022 Jul;32(5):299–308. DOI: 10.1016/j.tcm.2021.06.001. Epub 2021 Jun 22. PMID: 34166791.</mixed-citation><mixed-citation xml:lang="en">D’Ascenzi F, Valentini F, Pistoresi S, et al. Causes of sudden cardiac death in young athletes and nonathletes: systematic review and meta-analysis: Sudden cardiac death in the young. Trends Cardiovasc Med. 2022 Jul;32(5):299–308. DOI: 10.1016/j.tcm.2021.06.001. Epub 2021 Jun 22. PMID: 34166791.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Norrish G, Ding T, Field E, et al. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiol. 2019 Sep 1;4(9):918–927. DOI: 10.1001/jamacardio.2019.2861. PMID: 31411652; PMCID: PMC6694401.</mixed-citation><mixed-citation xml:lang="en">Norrish G, Ding T, Field E, et al. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiol. 2019 Sep 1;4(9):918–927. DOI: 10.1001/jamacardio.2019.2861. PMID: 31411652; PMCID: PMC6694401.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation. 2020 Jul 21;142(3):217–229. DOI: 10.1161/CIRCULATIONAHA.120.047235. Epub 2020 May 18. PMID: 32418493; PMCID: PMC7365676.</mixed-citation><mixed-citation xml:lang="en">Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation. 2020 Jul 21;142(3):217–229. DOI: 10.1161/CIRCULATIONAHA.120.047235. Epub 2020 May 18. PMID: 32418493; PMCID: PMC7365676.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Norrish G, Qu C, Field E, Cervi E, et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2022 Mar 30;29(4):678–686. DOI: 10.1093/eurjpc/zwab181. PMID: 34718528; PMCID: PMC8967478.</mixed-citation><mixed-citation xml:lang="en">Norrish G, Qu C, Field E, Cervi E, et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2022 Mar 30;29(4):678–686. DOI: 10.1093/eurjpc/zwab181. PMID: 34718528; PMCID: PMC8967478.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Monda E, Rubino M, Lioncino M, etal. Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. Front Pediatr. 2021 Feb 25;9:632293. DOI: 10.3389/fped.2021.632293. PMID: 33718303; PMCID: PMC7947260.</mixed-citation><mixed-citation xml:lang="en">Monda E, Rubino M, Lioncino M, etal. Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. Front Pediatr. 2021 Feb 25;9:632293. DOI: 10.3389/fped.2021.632293. PMID: 33718303; PMCID: PMC7947260.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ingles J, Goldstein J, Thaxton C, et al. Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circ Genom Precis Med. 2019 Feb;12(2):e002460. DOI: 10.1161/CIRCGEN. 119.002460. PMID: 30681346; PMCID: PMC6410971.</mixed-citation><mixed-citation xml:lang="en">Ingles J, Goldstein J, Thaxton C, et al. Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circ Genom Precis Med. 2019 Feb;12(2):e002460. DOI: 10.1161/CIRCGEN. 119.002460. PMID: 30681346; PMCID: PMC6410971.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tariq M., Ware S. Importance of genetic evaluation and testing in pediatric cardiomyopathy. World J Cardiol 2014; 6(11): 1156–1165.</mixed-citation><mixed-citation xml:lang="en">Tariq M., Ware S. Importance of genetic evaluation and testing in pediatric cardiomyopathy. World J Cardiol 2014; 6(11): 1156–1165.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kaski JP, Syrris P, Esteban MT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009 Oct;2(5):436–41. DOI: 10.1161/CIRCGENETICS.108.821314. Epub 2009 Jul 16. PMID: 20031618.</mixed-citation><mixed-citation xml:lang="en">Kaski JP, Syrris P, Esteban MT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009 Oct;2(5):436–41. DOI: 10.1161/CIRCGENETICS.108.821314. Epub 2009 Jul 16. PMID: 20031618.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gao J, Collyer J, Wang M, et al. Genetic Dissection of Hypertrophic Cardiomyopathy with Myocardial RNASeq. Int J Mol Sci. 2020 Apr 25;21(9):3040. DOI: 10.3390/ijms21093040. PMID: 32344918; PMCID: PMC7246737.</mixed-citation><mixed-citation xml:lang="en">Gao J, Collyer J, Wang M, et al. Genetic Dissection of Hypertrophic Cardiomyopathy with Myocardial RNASeq. Int J Mol Sci. 2020 Apr 25;21(9):3040. DOI: 10.3390/ijms21093040. PMID: 32344918; PMCID: PMC7246737.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sepp R, Hategan L, Csányi B, et al. The Genetic Architecture of Hypertrophic Cardiomyopathy in Hungary: Analysis of 242 Patients with a Panel of 98 Genes. Diagnostics (Basel). 2022 May 3;12(5):1132. DOI: 10.3390/diagnostics12051132. PMID: 35626289; PMCID: PMC9139509.</mixed-citation><mixed-citation xml:lang="en">Sepp R, Hategan L, Csányi B, et al. The Genetic Architecture of Hypertrophic Cardiomyopathy in Hungary: Analysis of 242 Patients with a Panel of 98 Genes. Diagnostics (Basel). 2022 May 3;12(5):1132. DOI: 10.3390/diagnostics12051132. PMID: 35626289; PMCID: PMC9139509.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a metaanalysis on 7675 individuals. Clin Res Cardiol. 2018 Jan;107(1):30–41. DOI: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24. PMID: 28840316.</mixed-citation><mixed-citation xml:lang="en">Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a metaanalysis on 7675 individuals. Clin Res Cardiol. 2018 Jan;107(1):30–41. DOI: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24. PMID: 28840316.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sanchez DJ, Lozano IF. Implantable cardioverterdefibrillator in hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018 Aug 12;2018(3):31. DOI: 10.21542/gcsp.2018.31. PMID: 30393643; PMCID: PMC6209444.</mixed-citation><mixed-citation xml:lang="en">Sanchez DJ, Lozano IF. Implantable cardioverterdefibrillator in hypertrophic cardiomyopathy. Glob Cardiol Sci Pract. 2018 Aug 12;2018(3):31. DOI: 10.21542/gcsp.2018.31. PMID: 30393643; PMCID: PMC6209444.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 Feb 1;79(4):372–389. DOI: 10.1016/j.jacc.2021.12.002. PMID: 35086660.</mixed-citation><mixed-citation xml:lang="en">Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 Feb 1;79(4):372–389. DOI: 10.1016/j.jacc.2021.12.002. PMID: 35086660.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
